We are the most experienced company on the market offering a comprehensive set of analyses. We prepare HTA reports for all countries of the region as well as adjust existing reports or models to specific local requirements.
Initial analysis performed for the purpose of determining the full scope of the HTA report.
Based on systematic reviews of experimental and observational studies, also using Bayes methods.
Based on decision techniques, Markov models, DES and other modelling methods.
Pursuant to provisions of the act on reimbursement, a rationalisation analysis must be developed when the conducted budget impact analysis indicates increased cost of financing the considered health technology.
Analyses of the effects on the health care system. Within the BIA, the number of patients who will use the considered health technology and future budget expenditure for that population are estimated.
Owing to our experience and our clients’ trust, together we managed to develop several innovative and interesting solutions within the scope of market access and systemic solution consulting.
preparation of solutions acceptable for the payer during Market Access process (RSS eg)
consultancy and exercises related to successful evidence based communcation with payer
reports and solutions related to financing the most expensive diseases
participation in meeting with KOLs and HCS experts
Experts working in our company eagerly share their knowledge with you on training courses, conducted by HTA Consulting. These include wide-ranging EBM and HTA topics, as well as specific issues in this area, as pricing or benefits package.
Just “knowing” doesn’t cut it, the trick is to pass your knowledge and the experience gained on to others in an accessible way. We approach each issue related to the health care system with a careful diagnosis and each training programme is tailored in such a way as to fit best the participants’ needs (e.g. workshops on developing risk-sharing schemes, developing economic models, planning observational data and registers). We are open for every question and challenge.
EBM & HTA
Pricing
Mini HTA
Guaranteed benefits package
The many years of our experience resulted in new tools streamlining our analytical work. The hundreds of budget impact analyses performed by our team gave rise to an extensive database on medicinal products dating back to as far as 2007. Recently we started sharing our resources. We developed online services, as IKAR pro and The Dynamic Literature Catalogue, and mobile apps dedicated specifically for each of the target groups.
The website was developed through combining many years of experience in the field of health technology assessment and reimbursement. A systematic analysis of reimbursement data made it possible to develop tools and solutions presented in a clear and unified way. The user-friendly website saves time spent on searching for information.
Basing on our database resources and experience in developing web applications we offer you the possibility of developing mobile applications in the field of reimbursement dedicated at various groups of recipients and aims.
Dynamic Literature Catalogue is a perfect solution for those who need to always have the up-to-date summary of results of all studies for the product in question “at hand”, which allows for preparation of simple collations, summaries and presentations of results. DLQ makes it possible to quickly extract results of clinical studies, assess their credibility and compare selected reports.
Our DTP department offers professional and high-quality support with data presentation as well as state-of-the-art graphic design of posters and other conference materials. Its extensive experience in publishing reports and books allows for the comprehensive, approachable assistance by preparing materials for both online access or print.
In line with the global trends, apart form creating HTA reports we plan and conduct primary and secondary studies, the aim of which is collecting credible cost and epidemiological data. The purpose of their results is to facilitate decision-making in the process of introducing new technologies to the market and negotiating the manner of their financing.